Ionis Pharmaceuticals, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C

Ionis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an

CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversif

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp